

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **PROPOSED RETIREMENT OF SENIOR MANAGEMENT AND PROPOSED RE-DESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司\* (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Weichang Zhou (周偉昌) (“**Dr. Zhou**”) will retire on March 31, 2024. On that day, he will retire from his roles as Chief Technology Officer and President of Global Biologics Development and Operations of the Company. Following his retirement as senior management of the Company, Dr. Zhou will be re-designated as a non-executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer to continue to support the Company’s development. Dr. Zhou will remain as a member of the strategy committee of the Board.

Dr. Zhou has confirmed that he has no disagreement with the Board and there are no matters relating to his retirement as senior management of the Company and re-designation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). For details on the background and experiences of Dr. Zhou, please refer to the annual report of the Company for the year ended December 31, 2022. Dr. Zhou also currently serves as a non-executive director of WuXi XDC Cayman Inc., a company listed on the Main Board of the Stock Exchange (stock code: 2268).

As an experienced expert in the field of biologics development and manufacturing, Dr. Zhou has been diligent and professional in his duties since he joined the Group in December 2012. He has made immense contributions to the Company’s development. The Board as well as the entire management level and staff would like to express their sincere gratitude to Dr. Zhou for his dedications during his tenure of office over the past 11 years.

The Board would also like to announce that Dr. Sherry Gu (“**Dr. Gu**”) has been appointed and will take over Dr. Zhou’s position as Chief Technology Officer and Executive Vice President of Global Biologics Development Department of the Company upon Dr. Zhou’s retirement. Dr. Gu, aged 53, joined the Company in 2017 as the Vice President of CMC (Chemistry, Manufacturing and Controls) Management for the West Coast of the United States, and expanded her responsibilities to include the East Coast of the United States in 2019 and Europe in 2021. During such period, she led numerous early and late-stage CMC projects directly and achieved several project IND (Investigational New Drug), PPQ (Process Performance Qualification) and approval milestones, including from DNA to EUA (Emergency Use Authorization) approval of Sotrovimab through the VIR-GSK collaboration in the combat of the worldwide COVID-19 pandemic. Dr. Gu received her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and has been working in the biopharmaceutical field for over 25 years, including 2 years at Bristol Myers Squibb and 18 years at Eli Lilly and Company prior to joining the Company.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, January 15, 2024

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*